Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/7219| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Delaloge, S | - |
| dc.contributor.author | Cella, D | - |
| dc.contributor.author | Ye, Y | - |
| dc.contributor.author | Buyse, M | - |
| dc.contributor.author | Chan, A | - |
| dc.contributor.author | Barrios, C H | - |
| dc.contributor.author | Holmes, F A | - |
| dc.contributor.author | Mansi, J | - |
| dc.contributor.author | Iwata, H | - |
| dc.contributor.author | Ejlertsen, B | - |
| dc.contributor.author | Moy, B | - |
| dc.contributor.author | Chia, S K L | - |
| dc.contributor.author | Gnant, M | - |
| dc.contributor.author | Smichkoska, Snezhana | - |
| dc.contributor.author | Ciceniene, A | - |
| dc.contributor.author | Martinez, N | - |
| dc.contributor.author | Filipović, S | - |
| dc.contributor.author | Ben-Baruch, N E | - |
| dc.contributor.author | Joy, A A | - |
| dc.contributor.author | Langkjer, S T | - |
| dc.contributor.author | Senecal, F | - |
| dc.contributor.author | de Boer, R H | - |
| dc.contributor.author | Moran, S | - |
| dc.contributor.author | Yao, B | - |
| dc.contributor.author | Bryce, R | - |
| dc.contributor.author | Auerbach, A | - |
| dc.contributor.author | Fallowfield, L | - |
| dc.contributor.author | Martin, M | - |
| dc.date.accessioned | 2020-03-10T13:34:15Z | - |
| dc.date.available | 2020-03-10T13:34:15Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/7219 | - |
| dc.description.abstract | We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. | - |
| dc.language.iso | en | - |
| dc.publisher | Elsevier BV | - |
| dc.relation.ispartof | Annals of Oncology | - |
| dc.subject | early-stage breast cancer | - |
| dc.title | Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1093/annonc/mdz016 | - |
| dc.identifier.url | https://api.elsevier.com/content/article/PII:S0923753419311123?httpAccept=text/xml | - |
| dc.identifier.url | https://api.elsevier.com/content/article/PII:S0923753419311123?httpAccept=text/plain | - |
| dc.identifier.url | http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz016/28492154/mdz016.pdf | - |
| dc.identifier.url | http://academic.oup.com/annonc/article-pdf/30/4/567/28564988/mdz016.pdf | - |
| dc.identifier.volume | 30 | - |
| dc.identifier.issue | 4 | - |
| dc.identifier.fpage | 567 | - |
| dc.identifier.lpage | 574 | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.